Ke Hui

Ke Hui

Auto-generated profile, based on publicly available information

Ke Hui

Department of Neurosurgery, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2026 in Lasers in Medical Science
Verified
Journal Article
Open access
PDF file
ZWZhongyu Wang
Zhongyu Wang
RTRonggui Tao
Ronggui Tao
DJDali Jiang
Dali Jiang
YGYashou Guo
Yashou Guo
KXKi Xi
Ki Xi
DHDalin He
Dalin He
Glioblastoma (GBM) remains clinically intractable owing to dismal prognosis and frequent recurrence. This study aimed to develop a dual-wavelength blue laser platform (450 nm and 405 nm) that integrates laser ablation, photodynamic diagnosis (PDD), and photodynamic therapy (PDT) in preclinical models, with 405 nm designated for PDD and 450 nm for PDT. Ex vivo ablation and coagulation were performed on porcine brain tissue using a 450 nm laser, compared with a conventional 980 nm laser or bipolar forceps. Subcutaneous and orthotopic GBM mouse models were used to assess 405 nm irradiation for tumor visualization following 5-aminolevulinic acid (5-ALA) administration. In vitro and in vivo experiments evaluated the therapeutic efficacy of 450 nm laser-mediated PDT, with 630 nm laser-mediated PDT serving as the positive control. Tumor recurrence was assessed after surgical resection combined with PDT. The 450 nm laser produced deeper and narrower incisions with less thermal coagulation than the 980 nm laser or bipolar forceps. 405 nm irradiation enabled clear tumor visualization, with peak 5-ALA-induced fluorescence at 2 h post-administration in subcutaneous tumors and 4 h in orthotopic tumors. The 450 nm laser induced concentration-dependent cytotoxicity in GBM cells and elicited robust photodynamic effects. Notably, surgical resection followed by PDT significantly suppressed tumor recurrence. These results validate an integrated strategy that uses a 405 nm laser for intraoperative PDD and a 450 nm laser for precise ablation and subsequent PDT, positioning this dual-wavelength blue laser platform as a promising, comprehensive approach to improving GBM surgical outcomes.

8 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
XWXinyu Wang
Xinyu Wang
HMHongliang Mao
Hongliang Mao
FMFengchun Mu
Fengchun Mu
CYChen Yang
Chen Yang
LCLin Cheng
Lin Cheng
MYMing Yang
Ming Yang
Background: Patients presenting with concurrent lung and brain lesions pose a unique diagnostic and therapeutic challenge. The role of neurosurgical resection in the management of de novo non-small-cell lung cancer brain metastases (NSCLC-BM) remains poorly defined. Methods: Consecutive patients undergoing resection for NSCLC-BM between February 2018 and October 2025 were retrospectively analyzed. De novo NSCLC-BM was defined as radiographic detection of pulmonary and intracranial lesions concurrently or within 1 month during the initial diagnostic work-up. Clinical characteristics and outcomes were compared between de novo and metachronous brain metastases (BM). Multivariable Cox regression identified factors associated with overall survival (OS). Factors associated with long-term postoperative survival in the de novo subgroup were further explored using Firth logistic regression. Results: Among 248 surgically treated patients, 113 (45.6%) presented with de novo BM. Compared with metachronous BM, de novo patients more frequently presented with symptomatic and multifocal intracranial disease. Among 73 de novo patients with evaluable survival, median postoperative OS was 57.0 months (95% CI, 22.9–not reached). Postoperative OS and intracranial progression-free survival (iPFS) did not differ significantly between the two groups, and de novo presentation was not independently associated with postoperative survival. Driver-positive status and lower intracranial tumor burden were associated with durable postoperative survival in the de novo subgroup. Conclusions: Neurosurgical resection represents a reasonable option for appropriately selected patients with de novo NSCLC-BM. These findings provide real-world evidence to inform multidisciplinary, individualized decision-making in patients presenting with concurrent lung and brain lesions.